www.pharmaceutical-tech.com View this email online »
Hospitals Management

July 2012, e-Newsletter
Advertise   |    Archives

Priorclave was formed in 1988 by staff with many years of experience in the laboratory industry enabling quick establishment of reputation for producing quality and reliable autoclaves. It led Priorclave to being recognised as one of the UK's premier manufacturers of Laboratory Autoclaves and establishing a strong international presence throughout mainland Europe, Asia and the Middle East during the past fifteen years.

Priorclave are one of the UK’s leading manufacturers of Laboratory Autoclaves for use in the food, drink, dairy, health and pharmaceutical industries. They operate at up to 2.4 Bar, with capacities from 40 to 700L and over.

We also manufacture low pressure autoclaves and climatic cabinets for use in the electronics, packaging and plastics industries.

Priorclave Products Includes:

Bench Top | Front Loading Autoclaves | Top Loading Autoclaves | Double Ended Autoclaves | Autoclave Calibration

Post Your Enquiry

Knowledge Speaks
Good Clinical Practice-Compliant Clinical Studies in China

Since the State Food and Drug Administration (SFDA) in China regulated the clinical trial industry with an amendment of the Chinese Good Clinical Practice (GCP) guidance, both the quality and integrity of clinical research have improved significantly, resulting in the recognition of more and more Chinese trial results by the international pharmaceutical community. This paper outlines the major regulatory practices related to conducting clinical trials in China.
Fluid Bags
Industry Updates
Applied Instrument Technologies Introduces SpectraQâ„¢ Analytical Software
UPLAND, Calif.
July 31st, 2012
SpectraQ enables the effective use of AIT's Analectâ„¢ FTIR and FT-NIR instruments and sampling accessories for routine laboratory analysis and instrument validation. SpectraQ is a software application designed to collect...
Press Release
Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
Jul 30th, 2012,
Princeton, New Jersey
The objectives of this Phase 2 trial include an assessment of the safety and efficacy of ADXS-HPV (1x109 cfu) with and without cisplatin (40 mg/m2, weekly x5). The primary endpoint of this study is survival.
Events and Exhibition
Drug Carriers in Medicine & Biology
Aug 12th - Aug 17th, 2012

Waterville Valley Resort
Waterville Valley
New Hampshire
Gordon Research Conferences
Subscribe Unsubscribe Advertise Archives
Copyright © 2012. All rights reserved